Why Is ProMIS Neurosciences Stock (PMN) Up 180% Today?
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
ProMIS Neurosciences noted that PMN310 is currently undergoing a Phase 1b trial evaluating its safety, tolerability, pharmacokinetics, and disease-relevant biomarkers in patients with early Alzheimer's disease. The company expects interim results from this trial in Q2 2026 and final results in Q4 2026.
PMN stock was up 177.21% in pre-market trading on Monday, following a 6.38% drop on Friday. The stock has also decreased 53.67% year-to-date and 77.2% over the past 12 months. With today's rally came heavy trading, with more than 79 million shares traded, compared to a three-month daily average of about 3.5 million shares.
Is ProMIS Neurosciences Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts' consensus rating for ProMIS Neurosciences is Moderate Buy, based on two Buy ratings over the past three months. With that comes an average PMN stock price target of $3.50, representing a potential 695.27% upside for the shares.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
My parents sold their home of 40 years and retired to Colombia. I moved them back to the US when they both got sick.
When my parents retired at 70, they both knew immediately where they wanted to go. With its year-round temperatures of 80 to 90 degrees, peaceful blue waters and a welcoming and lively culture the seaside city of Barranquilla, Colombia, called to them. After all, my Colombian father would be going back to his homeland, and my Cuban mother relished in the Latin culture that seemed so fragmented in the U.S. They sold their home of more than 40 years in Houston and purchased a two-story condo with a partial ocean view for $135,000 USD. Their social security and retirement money went a long way in Barranquilla, where the average cost of living is much lower than it is in the US. The move was great, until it wasn't In the beginning, their retirement life was idyllic. They enjoyed afternoon coffee with friends at sidewalk cafes, they walked along the beach every morning and they would attend parties in their condo development with fellow retirees. But one day, while they were visiting my family in Texas, my mother stopped and stared at my younger son splashing away in the pool. "Who's that little boy?" she asked. I stared at her face, as she scrutinized my son, with his dark curls and almond brown eyes that looked like mine. "Ma, that's your grandson," I said. That's when I knew something was terribly wrong. On another visit, my father would wander in the kitchen aimlessly, looking for the cabinet where we kept our water glasses, despite the fact that he had no problem finding them a year ago. A trip to the neurologist confirmed what I had already suspected. They both had Alzheimer's disease. We needed to make a plan While the diagnosis for both of them was still early-stage, I knew what the future held. My grandmother (my mother's mother) and my mother's brother both had Alzheimer's. Worst yet, my father seemed to be progressing at an alarmingly rapid rate. Unfortunately, retiring on the Colombian coast would be a dream unfulfilled. They decided to move back to Houston to be closer to family and their doctors. They agreed to sell their condo and move in with us temporarily until we could find a suitable assisted living apartment. But it's been tricky. Some days, they would say they were moving back to Barranquilla permanently. It was a constant flip-flop, but my husband and I made an executive decision to keep them in Houston. They've been living with us since February. In that time, I've had to reset all their passwords because they couldn't remember them. I spend every morning scrambling to the kitchen to make sure I'm there to give them their medication, a routine they consistently forget. The biggest challenge, though, has been navigating foreign laws. One thing I did early on was get a power of attorney and medical power of attorney. While those two documents have been incredibly helpful in the states, I'm not entirely sure the legal weight these documents may carry in Colombia. I'm currently looking for a lawyer and a real estate agent abroad who can help me with the sale of their condo. Once that's taken care of, I then have to sell all the stuff they've amassed in the 15 years they've lived there. I'm planning for my own future, too Perhaps the biggest lesson I've learned in all of this is to be prepared. I plan to sign up for long-term care insurance so my children won't have to stress over how they plan to pay for my care in the same way I have had to with my parents. I've been taking steps to improve my health and I'm also financially prepared for the inevitable — when my parents pass away. Right now, though, I'm going to relish the time I still have with them, here, close to my family.
Newsweek
5 hours ago
- Newsweek
Smart Speakers Like Alexa and Google Assistant Could Tell if You Have Parkinson's
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A new AI-powered, speech-based screening tool could help people assess whether they are showing signs of Parkinson's disease at home. Developed as part of a study by University of Rochester computer scientists, the web-based test asks users to recite two pangrams, short sentences using every letter of the alphabet. In just seconds, the AI can analyze the voice recordings to look for subtle patterns linked to Parkinson's—with nearly 86 percent accuracy. The researchers believe such a tool could be implemented as a feature in popular speech-based interfaces like Amazon Alexa or Google Home (with users consent). Parkinson's is typically diagnosed by specially trained neurologists through a combination of examinations, brain imaging and family history. While the new tool is not intended to be a replacement for a clinical diagnosis, the researchers see it as a fast, low-barrier and accessible way to flag people who might have the disease and encourage them to seek thorough clinical evaluation. Man connecting Alexa-like device to phone at home. Man connecting Alexa-like device to phone at 1.1 million people in the U.S. are living with Parkinson's disease, expected to rise to 1.2 million by 2030, according to Parkinson's Foundation. Nearly an estimated 90,000 people are diagnosed across the country each year, making it the second-most common neurodegenerative disease after Alzheimer's. While incidence increases with age, some four percent of people are diagnosed before 50. "There are huge swaths of the U.S. and across the globe where access to specialized neurological care is limited," said Rochester computer science professor Ehsan Hoque in a statement. "With users' consent, widely used speech-based interfaces like Amazon Alexa or Google Home could potentially help people identify if they need to seek further care." Most people living with Parkinson's in the U.S. seek their care from neurologists, with approximately 50 percent seeing a community neurologist and 9 percent seeing a movement disorders specialist, a previous Parkinson's Foundation study found. However, nearly 40 percent of people with the disease do not see a neurologist for their care but see a primary care provider (29 percent) or no provider (11 percent.) Home speaker device. Home speaker device. fabioderby/Getty Images To train and validate the new tool the researchers collected data from more than 1,300 participants—with and without Parkinson's—across home care settings, clinical settings at the University of Rochester Medical Center and the InMotion Parkinson's disease care center in Ohio. Using their computer's microphone, participants were asked to read aloud the following sentences: "The quick brown fox jumps over the lazy dog. The dog wakes up and follows the fox into the forest, but again the quick brown fox jumps over the lazy dog." By utilizing advanced semi-supervised audio models trained on millions of digital recordings to understand the characteristics of speech, the tool can obtain enough vocal cues from the short sentences to flag warning signs. "For example, the way someone with Parkinson's would utter sounds, pause, breathe, and inadvertently add features of unintelligibility is different in someone without Parkinson's," explained paper author and computer science master's degree student Abdelrahman Abdelkader in a statement. The tool was 85.7 percent accurate when tested, providing a strong indication of whether someone may have Parkinson's, according to the study authors. Woman using Google Nest-like device at home. Woman using Google Nest-like device at well as speech, some people can display signs of Parkinson's through motor movement tasks or facial expressions. Over the past decade, this has led Hoque's lab to pursue algorithms to combine multiple indicators with state-of-the-art results. "Research shows that nearly 89 percent of people with Parkinson's have a deformity in their voice that can be indicative of the disease, making speech a strong starting point for digital screening," said paper author and computer scientist Tariq Adnan in a statement. "By combining this method with assessments of other symptoms, we aim to cover the majority of people through our accessible screening process." An interactive, browser-based demonstration of the lab's three screening tests, including this new speech test, is available to try out at home here. Newsweek has reached out to the study authors for more information. Do you have a health story to share with Newsweek? Do you have a question about Parkinson's? Let us know via health@ References Adnan, T., Abdelkader, A., Liu, Z., Hossain, E., Park, S., Islam, M. S., & Hoque, E. (2025). A novel fusion architecture for detecting Parkinson's Disease using semi-supervised speech embeddings. Npj Parkinson's Disease, 11(1), 176. Pearson, C., Hartzman, A., Munevar, D., Feeney, M., Dolhun, R., Todaro, V., Rosenfeld, S., Willis, A., & Beck, J. C. (2023). Care access and utilization among medicare beneficiaries living with Parkinson's disease. Npj Parkinson's Disease, 9(1), 108.
Newsweek
7 hours ago
- Newsweek
Tiny 'Flowers' Offer New Hope Against Alzheimer's and Parkinson's
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Tiny, metallic, flower-shaped nanoparticles may offer fresh hope for patients with neurodegenerative diseases like Alzheimer's and Parkinson's. This is the conclusion of researchers from Texas A&M University, who found that the so-called nanoflowers can protect and heal brain cells. The do this by promoting the health and turnover of mitochondria—the oft-dubbed "powerhouses of the cell" which are responsible for turning food into energy. While this process is essential for life, the mitochondria also produce waste in the process—including so-called "reactive oxygen species"—which can damage cells. The finding could pave the way for new treatments for neurological diseases that address the underlying root causes—in this case mitochondrial health and oxidative stress—instead of just managing symptoms. "We expect that our drug can reverse neuronal damage and consequently reverse neurodegeneration," study lead and biochemist professor Dmitry Kurouski told Newsweek. Alzheimer's is the most common neurodegenerative disease with Parkinson's coming in second—and promising new treatments are much sought after. In fact, more than seven million Americans are living with Alzheimer's, a figure projected to rise to nearly 13 million by 2050, according to the Alzheimer's Association. Meanwhile, around 1.1 million people in the U.S. are living with Parkinson's, expected to rise to 1.2 million by 2030, according to Parkinson's Foundation. Alongside potentially helping combat Alzheimer's and Parkinson's, Kurouski said, "it is important to mention that similar reversing effects could be expected in other pathologies including acute brain and spinal cord injuries." Doctor and older patient smile while looking at phone results, with inserted image of nanoflowers overlayed in corner. Doctor and older patient smile while looking at phone results, with inserted image of nanoflowers overlayed in corner. Lacheev / iStock / Getty Images Plus / Journal of Biological Chemistry In their study, Kurouski and colleagues explored—in a petri dish in the lab—how nanoflowers affect both the brain's nerve cells, or 'neurons', and the star-shaped 'astrocytes' that support them. Within 24 hours of treatment, the team saw a "dramatic" drop in the levels of ROS, accompanied by signs of improved mitochondrial function. "Even in healthy cells, some oxidative stress is expected. But the nanoflowers seem to fine-tune the performance of mitochondria, ultimately bringing the levels of their toxic byproducts down to almost nothing," Kurouski explained. Having assessed the effects on individual cells, the researchers next tested the impact of the nanoflowers on whole creatures—specifically a species of worm, C. elegans, which is commonly used as a model organism in neurological research. The team found that, on average, worms treated with one specific flavor of nanoflower survived for days longer than their untreated counterparts (which typically live for around 18 days) and were less likely to die during the early stages of their lives. "These nanoflowers look beautiful under a microscope, but what they do inside the cell is even more impressive," Kurouski said in a statement. "By improving the health of brain cells, they help address one of the key drivers of neurodegenerative diseases that have long resisted therapeutic breakthroughs." With more research needed before clinical trials could be conducted on humans, Kurouski says he plans to undertake further studies in more complex animal models. The team are also exploring practical concerns towards clinical applications. "We are currently working on finding the best way to administrate the drug. We anticipate that internasal spray will be the best solution," Kurouski said. The biochemist stressed that he is keen to make sure the nanoflowers are safe, effective and have clear mechanism of action—but, he concluded, he thinks they could be a "new class of therapeutics" with "incredible potential." Do you have a health story to share with Newsweek? Do you have a question about the study? Let us know via health@ Reference Mitchell, C. L., Matveyenka, M., & Kurouski, D. (2025). Neuroprotective properties of transition metal dichalcogenide nanoflowers alleviate acute and chronic neurological conditions linked to mitochondrial dysfunction. Journal of Biological Chemistry, 301(5).
